A Trajectory of Long-Term Antipsychotic Medication Dosage in Inpatients with Severe Behavioral and Psychological Symptoms of Dementia: A Retrospective Study

Abstract

Introduction While antipsychotics are often prescribed for behavioral and psychological symptoms of dementia (BPSD), typically on an off-label basis, these medications have serious adverse effects. This study investigated the long-term use of antipsychotics among inpatients with dementia displaying severe BPSD, focusing on how prescriptions change over time.

Methods Medical charts at Kusakabe Memorial Hospital were retrospectively reviewed from October 2012 to September 2021. The study included patients diagnosed with dementia, admitted for BPSD, and were continuing antipsychotics at 3 months of their admission. Antipsychotic dosages were categorized as high (≥300 mg/d), medium (100–300 mg/d), and low (<100 mg/d) based on chlorpromazine equivalents and tracked until 15 months during hospitalization. Binary logistic regression was used to identify factors associated with dosage reductions between months 3 and 6.

Results This study involved 188 patients, with an average age of 81.2 years, 67% of whom were diagnosed with Alzheimer&apos;s dementia. At 3 months, 15.4% were taking high, 44.1% on medium, and 40.4% on low dosages of antipsychotics. The highest average dosage was observed at 3 months, with a subsequent decrease over time. By the 12th month, 20–30% of patients in all dosage categories had stopped their antipsychotic medication. Significant factors for dosage reduction included higher initial doses (OR 1.003, 95%Cl: 1.001–1.006, P=0.01) and male gender (OR 2.481, 95%Cl: 1.251–4.918, P=0.009).

Discussion A trajectory of antipsychotic dosage in inpatients with severe BPSD has rarely been reported. This research emphasizes the need for personalized strategies in managing long-term pharmacotherapy for this vulnerable group of patients.

Keywords

antipsychotics - behavioral and psychological symptoms of dementia - dose - hospitalization - long-term

Publikationsverlauf

Eingereicht: 04. März 2024
Eingereicht: 26. April 2024

Angenommen: 26. Mai 2024

Artikel online veröffentlicht:
25. Juni 2024

• References

• 1 Prince M, Wimo A, Guerchet M. et al. World Alzheimer Report 2015, The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. https://www.alzint.org/u/WorldAlzheimerReport2015.pdf
• 2 Lyketsos CG, Steinberg M, Tschanz JT. et al. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708-714
• 3 White N, Leurent B, Lord K. et al. The management of behavioural and psychological symptoms of dementia in the acute general medical hospital: a longitudinal cohort study. Int J Geriatr Psychiatry 2017; 32: 297-305
• 4 Devshi R, Shaw S, Elliott-King J. et al. Prevalence of behavioural and psychological symptoms of dementia in individuals with learning disabilities. Diagnostics (Basel) 2015; 5: 564-576
• 5 Rosdinom R, Zarina MZN, Zanariah MS. et al. Behavioural and psychological symptoms of dementia, cognitive impairment and caregiver burden in patients with dementia. Prev Med 2013; 57: S67-S69
• 6 Huang S-S, Lee M-C, Liao Y-C. et al. Caregiver burden associated with behavioral and psychological symptoms of dementia (BPSD) in Taiwanese elderly. Arch Gerontol Geriatr 2012; 55: 55-59
• 7 Baharudin AD, Din NC, Subramaniam P. et al. The associations between behavioral-psychological symptoms of dementia (BPSD) and coping strategy, burden of care and personality style among low-income caregivers of patients with dementia. BMC Public Health 2019; 19: 447
• 8 Quante A, Sulejmani A. Prevalence and pharmacotherapy of behavioral and psychological symptoms of dementia in a geriatric psychiatry unit: A retrospective analysis. Prim Care Companion CNS Disord 2017; 19: 17m02137
• 9 Dyer SM, Harrison SL, Laver K. et al. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2018; 30: 295-309
• 10 Yunusa I, Alsumali A, Garba AE. et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: A network meta-analysis. JAMA Netw Open 2019; 2: e190828
• 11 Pinheiro D. Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD). Encephale 2008; 34: 409-415
• 12 Trinh N-H, Hoblyn J, Mohanty S. et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA 2003; 289: 210-216
• 13 Ballard C, Hanney ML, Theodoulou M. et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151-157
• 14 Bjerre LM, Farrell B, Hogel M. et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician 2018; 64: 17-27
• 15 Ballard C, Lana MM, Theodoulou M. et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 5: e76
• 16 Devanand DP, Mintzer J, Schultz SK. et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med 2012; 367: 1497-1507
• 17 Devanand DP, Pelton GH, Cunqueiro K. et al. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer’s disease. Int J Geriatr Psychiatry 2011; 26: 937-943
• 18 Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci 2015; 69: 440-447
• 19 Mast G, Fernandes K, Tadrous M. et al. Persistence of antipsychotic treatment in elderly dementia patients: A retrospective, population-based cohort study. Drugs Real World Outcomes 2016; 3: 175-182
• 20 Schneider LS, Tariot PN, Dagerman KS. et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355: 1525-1538
• 21 Reus VI, Fochtmann LJ, Eyler AE. et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016; 173: 543-546
• 22 National Institute for Health and Care Excellence (NICE). 2018. Dementia: Assessment, management and support for people living with dementia and their carers; https://www.nice.org.uk/guidance/ng97
• 23 Frederiksen KS, Cooper C, Frisoni GB. et al. A European Academy of Neurology guideline on medical management issues in dementia. Eur J Neurol 2020; 27: 1805-1820
• 24 Rainer M, Haushofer M, Pfolz H. et al. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function. Eur Psychiatry 2007; 22: 395-403
• 25 Brodaty H, Ames D, Snowdon J. et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-143
• 26 Katz IR, Jeste DV, Mintzer JE. et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-115
• 27 De Deyn PP, Rabheru K, Rasmussen A. et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-955
• 28 Chan WC, Lam LC, Choy CN. et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001; 16: 1156-1162
• 29 Suh G-H, Son HG, Ju Y-S. et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004; 12: 509-516
• 30 Mintzer J, Greenspan A, Caers I. et al. Risperidone in the treatment of psychosis of Alzheimer disease: Results from a prospective clinical trial. Am J Geriatr Psychiatry 2006; 14: 280-291
• 31 Deberdt WG, Dysken MW, Rappaport SA. et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 2005; 13: 722-730
• 32 Street JS, Clark WS, Gannon KS. et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-976
• 33 Ballard C, Margallo-Lana M, Juszczak E. et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: Randomised double blind placebo controlled trial. BMJ 2005; 330: 874
• 34 Kurlan R, Cummings J, Raman R. et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356-1363
• 35 Tariot PN, Schneider L, Katz IR. et al. Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006; 14: 767-776
• 36 Zhong KX, Tariot PN, Mintzer J. et al. Quetiapine to treat agitation in dementia: A randomized, double-blind, placebo-controlled study. Curr Alzheimer Res 2007; 4: 81-93
• 37 De Deyn P, Jeste DV, Swanink R. et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer’s disease: A randomized, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 463-467
• 38 Streim JE, Porsteinsson AP, Breder CD. et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008; 16: 537-550
• 39 Mintzer JE, Tune LE, Breder CD. et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007; 15: 918-931
• 40 Eikelboom WS, Pan M, Ossenkoppele R. et al. Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis. Alzheimers Res Ther 2022; 14: 48
• 41 Japanese Society of Neurology. 2017. Guidelines for Treatment of Dementia Diseases. https://www.neurology-jp.org/guidelinem/nintisyo_2017.html